A discovery by scientists at Dana-Farber Cancer Institute and University of Texas Southwestern Medical Center presents drug developers with an entirely new tack in targeting one of the most-wanted molecular culprits in cancer.
(Dana-Farber Cancer Institute) Two research groups from Dana-Farber Cancer Institute have independently discovered a genetic mechanism in cancer cells that influences whether they resist or respond to immunotherapy drugs known as checkpoint inhibitors. Show More Summary
(Dana-Farber Cancer Institute) Scientists at Dana-Farber Cancer Institute have shown that experimental diabetes drugs can make cancer cells more vulnerable to traditional chemotherapy agents, and they say such combinations should be explored to potentially improve outcomes for cancer patients.
(Dana-Farber Cancer Institute) Benjamin Ebert, M.D., Ph.D., current chair of Medical Oncology, was presented with recognition at annual American Society of Hematology meeting. Ebert is notable for his leadership in describing the genomic landscape of adult myelodysplastic syndromes (MDS).
ATLANTA -- Researchers at Dana-Farber Cancer Institute have carried out the largest genomic analysis of patients with smoldering multiple myeloma (SMM), a precursor to full-blown blood cancer that doesn't show outward symptoms. The next-generation...Show More Summary
(Dana-Farber Cancer Institute) Among younger patients newly diagnosed with chronic lymphocytic leukemia (CLL), treatment with a combination of chemotherapy and a molecularly targeted drug significantly improves response over what is typically seen with chemotherapy alone, according to an investigator-initiated multi-center phase II clinical trial.
(Dana-Farber Cancer Institute) Researchers at Dana-Farber Cancer Institute have carried out the largest genomic analysis of patients with smoldering multiple myeloma (SMM), a precursor to full-blown blood cancer that doesn't show outward symptoms. Show More Summary
(Dana-Farber Cancer Institute) Although people with multiple myeloma usually respond well to treatment, the blood cancer generally keeps coming back. Following genetic changes in how the disease evolves over time will help to understand the disease and, eventually, deliver more effective treatments. Show More Summary
(Dana-Farber Cancer Institute) Clinical Activity in a Phase 1 Study of BLU-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis. Study shows one of multiple ways in which novel targeted cancer therapies are now being deployed to improve outcomes and quality of life for patients with rare, advanced, or difficult-to-treat blood malignancies.
(Dana-Farber Cancer Institute) Immunotherapy agents known as checkpoint inhibitors have shown considerable promise in patients with hematologic cancers who relapse after a transplant with donor stem cells. Preliminary results from the...Show More Summary
(Brigham and Women's Hospital) Investigators from Brigham and Women's Hospital and Dana-Farber Cancer Institute are leveraging the power of artificial intelligence to develop a new technique to detect ovarian cancer early and accurately. Show More Summary
Following a successful clinical trial involving Dana-Farber Cancer Institute and Brigham and Women's Hospital, the first chimeric antigen receptor (CAR) T-cell therapy for adult cancers was approved by the Food and Drug Administration (FDA) today. Show More Summary
(Dana-Farber Cancer Institute) In discovering how certain chemotherapy drugs cause the nerve damage known as peripheral neuropathy, researchers at Dana-Farber Cancer Institute have found a potential approach to preventing this common and troublesome side effect of cancer treatment.
An NCCN ORP-funded study, examining effectiveness of bavituximab combination in patients with newly diagnosed glioblastomas, enrolled its first patient at Dana-Farber Cancer Institute in Boston, Massachusetts.
The American Thyroid Association has awarded a 2017 Research Grant, funded by the Thyroid Cancer Survivors' Association, Inc. (ThyCa), to Glenn J. Hanna, MD. Dr. Hanna is a Staff Physician at the Dana-Farber Cancer Institute (DFCI)'s Center for Head & Neck Oncology, as well as an Instructor in Medicine at Harvard Medical School.
The Dana-Farber Cancer Institute is pleased to announce the opening of the new Leonard P. Zakim Center for Integrative Therapies and Healthy Living, underscoring Dana-Farber's commitment to providing cutting-edge patient therapies and support for the "whole person" during and after treatment. Show More Summary
(Dana-Farber Cancer Institute) A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center -- using CRISPR-Cas9 genome editing technology to test the function of thousands of tumorShow More Summary
Researchers at Harvard Stem Cell Institute, Dana-Farber Cancer Institute, and Harvard Medical School have identified a previously unknown mechanism that plays an important role in the regeneration of the inner intestinal lining. Their findings provide new insights on how this tissue, which undergoes change on a daily basis, maintains itself.
(Dana-Farber Cancer Institute) A personal cancer treatment vaccine that targets distinctive 'neoantigens' on tumor cells has been shown to stimulate a potent, safe, and highly specific immune anti-tumor response in melanoma patients, report scientists from Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.
(Dana-Farber Cancer Institute) Some patients with a form of advanced kidney cancer benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by Dana-Farber Cancer Institute scientists.